Table 1 Baseline characteristics of study participants stratified by survival status
Baseline characteristics | Total (n = 3321) | Survivorsa (n = 2562) | Non-survivorsa (n = 759) | p-value |
|---|---|---|---|---|
Age, mean (SD), years | 61.7 ± 11.7 | 59.2 ± 10.6 | 70.4 ± 11.3 | < 0.001 |
Male, n (%) | 2404 (72.4%) | 1874 (73.1%) | 530 (69.8%) | 0.073 |
Current smokers, n (%) | 992 (29.9%) | 830 (32.4%) | 162 (21.3%) | < 0.001 |
BMI, mean (SD), kg/m² | 25.6 ± 3.5 | 25.9 ± 3.4 | 24.8 ± 3.8 | < 0.001 |
SBP, mean (SD), mm Hg | 135.0 ± 22.3 | 134.2 ± 22.1 | 137.9 ± 22.5 | < 0.001 |
DBP, mean (SD), mm Hg | 75.7 ± 17.0 | 76.5 ± 18.1 | 72.8 ± 12.4 | < 0.001 |
LVEF, median (IQR), % | 58.0 (54.0–62.0) | 59.0 (55.0–63.0) | 55.0 (44.0–59.0) | < 0.001 |
Medical history, n (%) | ||||
Diabetes mellitus | 1077 (32.4%) | 758 (29.6%) | 319 (42.0%) | < 0.001 |
Hypertension | 2175 (65.5%) | 1,623 (63.3%) | 552 (72.7%) | < 0.001 |
Previous MI | 568 (17.1%) | 367 (14.3%) | 201 (26.5%) | < 0.001 |
Stroke | 319 (9.6%) | 185 (7.2%) | 134 (17.7%) | < 0.001 |
ACS, n (%) | 2,479 (74.6%) | 1,858 (72.5%) | 621 (81.8%) | < 0.001 |
Medication, n (%) | ||||
ACE-I/ARB | 1,398 (42.1%) | 1,056 (41.2%) | 342 (45.1%) | 0.060 |
Beta blocker | 2,386 (71.8%) | 1,835 (71.6%) | 551 (72.6%) | 0.600 |
Statin | 3,130 (94.2%) | 2,448 (95.6%) | 682 (89.9%) | < 0.001 |
Laboratory indicators | ||||
Creatinine, mean (SD), mg/dL | 1.0 ± 0.8 | 0.9 ± 0.5 | 1.3 ± 1.3 | < 0.001 |
eGFR, mean (SD), mL/min/1.73m2 | 110.5 ± 538.4 | 116.9 ± 607.9 | 89.0 ± 144.4 | 0.210 |
Glucose, median (IQR), mg/dL | 105.8 (90.2–137.5) | 104.3 (89.8–132.3) | 113.8 (91.8–153.4) | < 0.001 |
LDL-C, mean (SD), mg/dL | 92.7 ± 36.0 | 93.0 ± 35.9 | 92.0 ± 36.4 | 0.530 |
TC, mean (SD), mg/dL | 155.9 ± 41.8 | 156.1 ± 41.1 | 155.3 ± 44.1 | 0.660 |
TG, mean (SD), mg/dL | 144.0 ± 110.5 | 148.1 ± 115.8 | 130.3 ± 89.0 | < 0.001 |
TyG index, mean (SD) | 8.9 ± 0.7 | 8.9 ± 0.6 | 8.8 ± 0.7 | 0.200 |